Factors influencing the level of sST2 in patients with ST segment elevation myocardial infarction
Article Sidebar
Main Article Content
Abstract
The aim – to study the influence of different factors on sST2 level in patients with ST segment elevation myocardial infarction.
Material and methods. The study involved 65 patients with ST segment elevation myocardial infarction, 54 (83.1 %) men and 11 (26.9 %) women, average age 57.0±30.5 years. All patients were hospitalized on the first day after stenting of infarct-related coronary artery. ST2 was detected by immune fermentation method. Its level less then 35 ng/ml was regarded as normal.
Results. All patient revealed positive correlation between sST2 level and heart rate (r=0.25; Р=0.05), left ventricular diastolic diameter (r=0.31; Р=0.03), left ventricular systolic diameter (r=0.38; Р=0.007) and negative – with left ventricular ejection fraction (r=–0.48; Р=0.0001). In the regressive model (Р<0.05), the level of ST2 was caused by low ejection fraction (20.64 %; Р=0.0001), angina pectoris before index event (11.03 %; Р=0.01), female gender (9.96 %; Р=0.01), low HDL-C (8.54 %; Р=0.05) and high level of creatinine (7.83 %; Р=0.046).
Conclusions. Received data show influence of sST2 upon left ventricular remodeling early after ST segment elevation myocardial infarction. Incremental regressive analysis allows to assess the influence of different factors on the sST2 level.
Article Details
Keywords:
References
Abela M. A biomarker guided approach in heart failure // Malta Med. J.– 2014.– Vol. 26, Issue 3.– P. 46–51.
Anand I.S., Rector T.S., Kuskowski M. et al. Prognostic value od soluble ST2 in the Valsartan Heart Failure Trial // Cirk. Heart Fail.– 2014.– Vol. 7.– P. 418–426.
Catapano A.L., Graham I., De Backer G. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. DOI: http://dx.doi.org/10.1093/eurheartj/ehw272 ehw272
Ciccone M.M., Cortese F., Gesualdo M. et al. A novel cardiac bio-marker: ST2: a revier // Molecules.– 2013.– Vol. 18.– P. 15324–15328.
Demyanets S., Speidl V.S., Tentzeris I. et al. Soluble ST2 and Interleukin-33 in coronary artery disease: relation to disease activity and adverse outcome // Plos One.– 2014.– Vol. 9 (4).– P. e95055. Doi:10.1371/journal.pone.0095055
Hamm C.W., Bassand J.P., Agewall S. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation // Eur. Heart J.– 2012.– Vol. 33.– P. 2569–2619.
Khera A.V., Cuchel M., de la Llera-Moya M. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis // New Engl. J. Med.– 2011.– Vol. 364.– P. 127–135.
Lichtman J.H., Lorenze N.P., D’Onofrio G.D. et al. Variation in recovery: role of gender on outcomes of young ami patients (VIRGO) study design // Circ. Cardiovasc. Qual. Outcomes.– 2010.– Vol. 3 (6).– P. 684–693.
Martin S.S., Joshi P.H., Blaha M.J. High-density lipoprotein and endothelial function in patients with myocardial infarction: Pieces in a puzzle // Atherosclerosis.– 2014.– Vol. 237, Issue 2.– P. 838–839.
Nicholls S.J., Tuzcu E.M., Sipahi I. et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis // JAMA.– 2007.– Vol. 297.– P. 499–508.
Ramirez A., Hu P.P. Low high-density lipoprotein and risk of myocardial infarction // Clin. Med. Insights Cardiol.– 2015.– Vol. 9.– P. 113–117.
Rohatgi A., Khera A., Berry J.D. et al. HDL cholesterol efflux capacity and incident cardiovascular events // New Engl. J. Med.– 2014.– Vol. 371.– P. 2383–2393.
Stone N.J., Robinson J.G., Lichtenstein A.H. et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in Adults // Circulation.– 2014.– Vol. 129.– P. S1–S45.
Weir R.A.P, Miller A.M., Murphy G.E.J. et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction // J. Am. Coll. Cardiol.– 2010.– Vol. 55.– P. 243–250.
Yamaguchi J., Kasanuki H., Ishii Y. et al. Serum Creatinine on Admission Predicts Long-Term Mortality in Acute Myocardial Infarction Patients Undergoing Successful Primary Angioplasty Data From the Heart Institute of Japan Acute Myocardial Infarction (HIJAMI) Registry // Circ. J.– 2007.– Vol. 71.– P. 1354–1359.
Yusuf S., Hawken S., Ôunpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study // Lancet.– 2004.– Vol. 364, N 9438.– P. 937–952.
Zhao L., Wang L., Zhang Y. Elevated admission serum creatinine predicts poor myocardial blood flow and one-year mortality in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention // J. Invasive Cardiol.– 2009.– Vol. 10.– P. 493–498.